Why Is Viking Therapeutics, Inc. (VKTX) Among the Best Multibagger Stocks to Buy Right Now?

Viking Therapeutics, Inc. (VKTX) has emerged as one of the most promising multibagger stocks in the biopharmaceutical sector, offering investors significant growth potential and a strong pipeline of innovative therapies. With a market capitalization of approximately $1.5 billion, VKTX is well-positioned to capitalize on the growing demand for novel treatments in metabolic and endocrine disorders. Here's why VKTX is an attractive investment opportunity:

1. Strong Pipeline and Clinical Results:
- VK2809 for NASH/MASH: In the Phase 2b VOYAGE study, VK2809 demonstrated statistically significant reductions in liver fat content at Week 52, with response rates ranging from 64% to 88%. The compound also showed promising histologic results, with NASH resolution rates ranging from 63% to 75% and fibrosis improvement rates ranging from 44% to 57%. These results position VK2809 as a potential best-in-class therapy for NASH/MASH, with a robust safety and tolerability profile.
- VK0214 for X-ALD: In the Phase 1b clinical trial, VK0214 showed significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids compared to placebo. The compound was safe and well-tolerated, with encouraging safety and tolerability data following 28 days of once-daily dosing. These results suggest that VK0214 has potential for treating X-ALD, a rare and often fatal metabolic disorder.

2. Strategic Partnerships and Collaborations:
- Viking Therapeutics has formed strategic partnerships and collaborations with leading pharmaceutical companies, such as Roche, Takeda, and Amgen. These partnerships provide access to capital, expertise, and resources, enabling VKTX to accelerate its drug development efforts, expand its product portfolio, and ultimately drive growth and success in the market.
- The company's strong financial position and cash runway support its growth and expansion plans. As of December 31, 2023, VKTX had approximately $375.5 million in cash, cash equivalents, and marketable securities, providing sufficient capital to fund its operations and growth initiatives.



3. Analyst Ratings and Target Prices:
- The average target price for VKTX stock is $106.75, with a low estimate of $74 and a high estimate of $138. This indicates a potential increase of 165.28% from the current stock price of $40.24, reflecting analysts' confidence in the company's growth prospects.
- The average analyst rating for VKTX stock is "Strong Buy," indicating that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.



In conclusion, Viking Therapeutics, Inc. (VKTX) is an attractive investment opportunity due to its strong pipeline of innovative therapies, strategic partnerships and collaborations, and positive analyst ratings and target prices. The company's focus on metabolic and endocrine disorders, along with its promising clinical results and robust financial position, positions VKTX as one of the best multibagger stocks to buy right now. As the company continues to advance its pipeline and expand its market reach, investors can expect significant growth and value creation in the coming years.